Predicting airway immune responses and protection from immune parameters in blood following immunization in a pig influenza model

Front Immunol. 2024 Dec 19:15:1506224. doi: 10.3389/fimmu.2024.1506224. eCollection 2024.

Abstract

Whereas the intranasally delivered influenza vaccines used in children affect transmission of influenza virus in the community as well as reducing illness, inactivated influenza vaccines administered by intramuscular injection do not prevent transmission and have a variable, sometimes low rate of vaccine effectiveness. Although mucosally administered vaccines have the potential to induce more protective immune response at the site of viral infection, quantitating such immune responses in large scale clinical trials and developing correlates of protection is challenging. Here we show that by using mathematical models immune responses measured in the blood after delivery of vaccine to the lungs by aerosol can predict immune responses in the respiratory tract in pigs. Additionally, these models can predict protection from influenza virus challenge despite lower levels of blood responses following aerosol immunization. However, the inclusion of immune responses measured in nasal swab eluates did not improve the predictive power of the model. Our models are an important first step, providing proof of principle that it is feasible to predict immune responses and protection in pigs. This approach now provides a path to develop correlates of protection for mucosally delivered vaccines in samples that are easily accessed in clinical trials.

Keywords: aerosol; bronchoalveolar lavage; influenza A virus; mucosal immunity; pig; protection.

MeSH terms

  • Administration, Intranasal
  • Animals
  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology
  • Disease Models, Animal*
  • Immunity, Mucosal
  • Immunization
  • Influenza Vaccines* / administration & dosage
  • Influenza Vaccines* / immunology
  • Lung / immunology
  • Lung / virology
  • Orthomyxoviridae Infections* / immunology
  • Orthomyxoviridae Infections* / prevention & control
  • Swine
  • Vaccination

Substances

  • Influenza Vaccines
  • Antibodies, Viral

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the UKRI Medical Research Council (grant number MR/S037160/1) and UKRI Biotechnology and Biological Sciences Research Council (BBSRC). Institute Strategic Programme and Core Capability Grants to The Pirbright Institute (BBS/E/I/00007031, BBS/E/I/00007037, BBS/E/PI/230001A and BBS/E/PI/230001C).